Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2015

Open Access 01-12-2015 | Research

MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients

Authors: Tamás Micsik, András Lőrincz, János Gál, Richard Schwab, István Peták

Published in: Diagnostic Pathology | Issue 1/2015

Login to get access

Abstract

Background

Rheumatoid Arthritis is a chronic disease leading to decreased quality of life with a rather variable response rate to Disease Modifying Anti Rheumatic Drugs. Methotrexate (MTX) is the gold standard therapy in Rheumatoid Arthritis. The Multidrug resistance Related Protein and Multi Drug Resistance protein 1, also called P-glycoprotein-170 transporters can alter the intracellular concentration of different drugs. Methotrexate is an MRP1 substrate and thus the functional activity of MRP1 might have a clinical impact on the efficiency of the Methotrexate-therapy in Rheumatoid Arthritis.

Methods

We have compared the functional Multidrug Activity Factors (MAF) of the MDR1 and MRP1 transporters of Peripheral Blood Leukocytes of 59 Rheumatoid Arthritis patients with various response rate to MTX-therapy (MTX-responder, MTX-resistant and MTX-intolerant RA-groups) and 47 non-RA controls in six different leukocyte subpopulations (neutrophil leukocytes, monocytes, lymphocytes, CD4+, CD8+ and CD19+ cells). There was a decreased MAF of RA patients compared to non- Rheumatoid Arthritis patients and healthy controls in the leukocyte subpopulations. There was a significant difference between the MAF values of the MTX-responder and MTX intolerant groups. But we have not found significant differences between the MAF values of the MTX-responder and MTX-resistant Rheumatoid Arthritis -groups.

Results

Our results suggest that MDR1 and MRP1 functional activity does not seem to affect the response rate to MTX-therapy of Rheumatoid Arthritis-patients, but it might be useful in predicting MTX-side effects. We have demonstrated the decreased functional MDR-activity on almost 60 Rheumatoid Arthritis patients, which can be interpreted as a sign of the immune-suppressive effect of the MTX-treatment.
Literature
1.
Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics. 2008;26:831–46.PubMedCrossRef
2.
Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis. 2003;62:15–9.PubMedPubMedCentralCrossRef
3.
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2008;58:S126–35.PubMedCrossRef
4.
5.
Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine. 2000;67:30–9.
6.
Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357–61.PubMed
7.
Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun Rev. 2004;3:188–92.PubMedCrossRef
8.
Jorgensen C, Maillefert JF. Multidrug resistances genes in rheumatology. Is their role immunological or pharmacological? Joint Bone Spine. 2000;67:8–10.PubMed
9.
Jorgensen C, Sun R, Rossi JF, Costes J, Richard D, Bologna C, et al. Expression of a multidrug resistance gene in human rheumatoid synovium. Rheumatol Int. 1995;15:83–6.PubMedCrossRef
10.
Jansen G, Scheper RJ, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand J Rheumatol. 2003;32:325–36.PubMedCrossRef
11.
Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele G Jr, et al. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer. 1995;71:670–5.PubMedPubMedCentralCrossRef
12.
Lee WP. P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vincristine. Biochim Biophys Acta. 1995;1245:57–61.PubMedCrossRef
13.
Zhang JT, Ling V. Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem. 1991;266:18224–32.PubMed
14.
Karaszi E, Jakab K, Homolya L, Szakacs G, Hollo Z, Telek B, et al. Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br J Haematol. 2001;112:308–14.PubMedCrossRef
15.
Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol. 1996;35:430–5.PubMedCrossRef
16.
Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum. 1999;42:2014–5.PubMedCrossRef
17.
Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532–5.PubMed
18.
Wolf J, Stranzl T, Filipits M, Pohl G, Pirker R, Leeb B, et al. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:564–8.PubMedPubMedCentralCrossRef
19.
Stranzl T, Wolf J, Leeb BF, Smolen JS, Pirker R, Filipits M. cesponse to methotrexate therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:27–32.
20.
van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. Nat Clin Pract Rheumatol. 2007;3:26–34.PubMedCrossRef
21.
Klimecki W, Futscher B, Grogan T, Dalton W. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83:2451–8.PubMed
22.
Laupeze B, Amiot L, Payen L, Drenou B, Grosset JM, Lehne G, et al. Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci. 2001;68:1323–31.PubMedCrossRef
23.
Hider SL, Owen A, Hartkoorn R, Khoo S, Back D, Silman AJ, et al. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. Ann Rheum Dis. 2006;65:1390–3.PubMedPubMedCentralCrossRef
Metadata
Title
MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients
Authors
Tamás Micsik
András Lőrincz
János Gál
Richard Schwab
István Peták
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-015-0447-1

Other articles of this Issue 1/2015

Diagnostic Pathology 1/2015 Go to the issue

Research

Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma

Research

Calreticulin down-regulation inhibits the cell growth, invasion and cell cycle progression of human hepatocellular carcinoma cells

Review

Pathologic manifestations of levamisole-adulterated cocaine exposure

Research

Association of C5aR1genetic polymorphisms with coronary artery disease in a Han population in Xinjiang, China

Research

Keap1 expression has independent prognostic value in pancreatic adenocarcinomas

Research

Utility of frozen section analysis for fungal organisms in soft tissue wound debridement margin determination